Mabworks
Latest round
- Series C
Last raised
- Apr 2020
Total raised
- $215M
Investors
- 18
About Mabworks
Established in 2003 and based in Beijing, China, Mabworks operates as a biopharmaceutical company dedicated to developing antibody drugs. It has more than 50 domestic and foreign invention patents. The chairman of the company, Feng Li graduated from Rice University and has worked in Genentech, Amgen, and Tanox. The CMO of the company, Jinjin Liang graduated from the University of California and has worked in Icon, WuXi Clinical, and IQVIA. In March 2023, Mabworks was listed on the New Third Board. The company focuses on the development of antibodies that stimulate the immune system to deplete target pathogenic cells. It has three technical platforms, including ADCC (antibody-dependent cell-mediated cytotoxicity) enhanced antibody platform, multi-specific antibody platform, and antibody discovery and optimization platform. The ADCC enhanced antibody platform is an antibody glycosylation modification platform, and the company is developing four clinical stage antibody drugs, including MIL62, MIL93, MIL97, and MBS301. Mabworks has developed 8 clinical stage drugs under research. The drugs cover the fields of tumours and autoimmune diseases.85 million.
Who invested in Mabworks
18 investors across 3 rounds
See all investors in Mabworks
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Mabworks
Who invested in Mabworks?
Mabworks has 18 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mabworks raised?
Mabworks has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Mabworks last raise money?
Mabworks's most recent round on record is a Series C, in Apr 2020.
What does Mabworks do?
Established in 2003 and based in Beijing, China, Mabworks operates as a biopharmaceutical company dedicated to developing antibody drugs.
Where is Mabworks headquartered?
Mabworks is headquartered in Beijing, China.
Which VCs invest in companies like Mabworks?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Mabworks's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Mabworks? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.